TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00525174

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bangerter filters
Description: Bangerter filter worn on sound eye spectacle lens full time

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: 2 hours daily patching of the sound eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: one hour near visual activities
Study: NCT02383433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT00525174

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near activities
Description: one hour near visual activities
Study: NCT02676765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allergen extract tablet
Description: 1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
Study: NCT02763826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
Study: NCT03222232

Intervention type: BEHAVIORAL
Intervention: catheter salvage
Description: In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
Study: NCT01858688

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI
Description: an MRI of the prostate will be performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Description: a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
Study: NCT02013804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0680 (AMP-514)
Description: Study has planned dose escalation cohorts
Study: NCT03368274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T 614
Description: Patients of IgG4-RD with mild symptoms are given one dose of diprospan and Iguratimod, 25mg, Bid.
Study: NCT01631409

Intervention type: OTHER
Intervention: Treatment of CHD risk factors
Description: Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.

Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
Description: In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).

Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.
Description: In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Study: NCT02122029

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Description: Behavioral techniques for weight management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: Vertical Banding Gastroplasty
Study: NCT02640690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY)
Description: (10) 1-hour sessions of trauma sensitive yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: (12) 1.5 hour sessions of cognitive processing therapy
Study: NCT01631409

Intervention type: PROCEDURE
Intervention: PCA
Description: Percutaneous coronary angioplasty

Intervention type: PROCEDURE
Intervention: CABG
Description: Coronary artery bypass grafting
Study: NCT02383433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03382067

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High Epicatechin/ Melissa
Description: Single consumption of a 55g bar of dark chocolate containing: 42.8g Acticoa chocolate + 7.2g caster sugar + 5g Melissa

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low Epicatechin/ Oat bran
Description: Single consumption of a 55g bar of white chocolate containing: 50g Lindor chocolate + 5g oat bran
Study: NCT02955680

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recorded maternal voice
Description: A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recorded stranger's voice
Description: A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.~ OO (first name of child), wake up\~. Let's go home with mommy. OO, wake up\~. Open your eyes. Take a deep breath.
Study: NCT04515953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND-340
Description: ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV-PCA
Description: IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.
Study: NCT03149952

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells
Description: Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
Study: NCT01102894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill
Description: SmartPill
Study: NCT04720768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: BRAF inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: CDK4/6 inhibitor
Study: NCT01711866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine up to 16 mg / 24 hours, 4 weeks.
Study: NCT04353882

Intervention type: OTHER
Intervention: Assess the difference in MOR-1 expression between healthy and tumor tissue
Description: Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.

Intervention type: OTHER
Intervention: Assess the difference in MOR-1 expression between healthy and tumor tissue
Description: Assess the difference in the quantitative expression of MOR-1 (by means of RT-qPCR) between healthy tissue and tumor tissue, in patients with stage II and III colorectal cancer undergoing scheduled surgery.
Study: NCT02666794

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural bupivacaine with vasoconstrictor 0.125%
Description: 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural sufentanil
Description: 20 mcg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of the epidural catheter
Description: Placement of the epidural catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine solution 0.5%
Description: 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: 60 mcg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of an epidural catheter to the catheter through technical needle
Description: Placement of an epidural catheter to the catheter through technical needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal sufentanil
Description: 5 mcg
Study: NCT01133015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve
Description: Fractional flow reserve measured by pressure wire

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS
Description: intravascular ultrasound
Study: NCT01076621

Intervention type: DRUG
Intervention: 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Description: Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
Study: NCT01986959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With Periodontal dressing
Description: After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without Periodontal dressing
Description: The dressing was not inserted.
Study: NCT02068261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cogmed working memory training
Description: Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
Study: NCT02015780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam
Description: Fasiglifam tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fasiglifam placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic therapy
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antihyperglycemic therapy
Description: Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
Study: NCT01631409

Intervention type: DEVICE
Intervention: Cardiospec
Description: Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.

Intervention type: DRUG
Intervention: Aspirin, Isosorbide mononitrate, Atenolol, Enalapril
Description: In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
Study: NCT04052269

Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil 100mg
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 100mg
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
Study: NCT02976623

Intervention type: OTHER
Group type: OTHER
Intervention: metric-based feedback training
Description: Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
Study: NCT01195428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 40 mg daily
Study: NCT01974258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Escalating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Orally administered once daily for 21 consecutive days, followed by 7 days off.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Orally administered once daily for 21 consecutive days, followed by 7 days off.
Study: NCT01195428

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02576561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TVGV-1
Description: Antigen + Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TVGV-1
Description: Antigen + Adjuvant
Study: NCT01974258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Administered by IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Administered by IV infusion every 2 weeks
Study: NCT02576561

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TVGV-1
Description: Antigen + Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPI-0100
Description: Adjuvant Alone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPI-0100
Description: Adjuvant Alone

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GPI-0100
Description: Adjuvant Alone

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04919278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic adjustments
Description: Chiropractic adjustment is a procedure in which trained specialists (chiropractors) use their hands or a small instrument to apply a controlled, sudden force to a spinal joint. The goal of this procedure, also known as spinal manipulation, is to improve spinal motion and improve your body's physical function.
Study: NCT01870583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iodine povidone
Description: Iodine skin preparation solution prior to cesarean delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine skin preparation solution prior to cesarean delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination iodine and chlorhexidine
Description: Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
Study: NCT02456142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caudal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous morphine
Study: NCT03287440

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPD Wellness
Description: This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COPD Wellness
Description: This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Advocate
Description: The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
Study: NCT01684631

Intervention type: DEVICE
Intervention: Total Hip arthroplasty
Study: NCT02615054

Intervention type: DEVICE
Intervention: 2D Echocardiogram
Description: All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
Study: NCT01974258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Administered by IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Administered by IV infusion every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Orally administered twice daily
Study: NCT02615054

Intervention type: DEVICE
Intervention: 2D Echocardiogram
Description: All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.

Intervention type: DEVICE
Intervention: 2D Echocardiogram
Description: All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.

Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing and post-CPET cardiac function
Description: To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.

Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing and post-CPET cardiac function
Description: To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.

Intervention type: DEVICE
Intervention: Cardiopulmonary exercise testing and post-CPET cardiac function
Description: To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
Study: NCT02492347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiogram
Description: The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocardiogram
Description: The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
Study: NCT04187560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LB-102
Description: (N-Methyl amisulpride)
Study: NCT01974258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Orally administered twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Orally administered twice daily
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
Study: NCT02068261

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
Study: NCT02261311

Intervention type: OTHER
Intervention: Quality of Life
Description: All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
Study: NCT03201445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: 200 mg tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match filgotinib tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Locally approved treatment, accepted by medical experts as a proper treatment for IBD conditions, prescribed according to best clinical practice, with no known testicular toxicity.
Study: NCT04005885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Contact Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Contact Lens
Study: NCT01159236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500 mg/m2 for 4 courses (once every 7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 500 mg/m2 for 4 courses (once every 7 days)
Study: NCT04005885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: somofilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: daily disposable contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A
Description: daily disposable contact lens
Study: NCT01881906

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Study: NCT02678156

Intervention type: DEVICE
Intervention: Lyoplant Onlay